Cart
sales@molnova.com
c-Met inhibitor 1
CAS No. 1357072-61-7
c-Met inhibitor 1( —— )
Catalog No. M22126 CAS No. 1357072-61-7
c-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 69 | In Stock |
|
| 5MG | 63 | In Stock |
|
| 10MG | 93 | In Stock |
|
| 25MG | 188 | In Stock |
|
| 50MG | 276 | In Stock |
|
| 100MG | 431 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product Namec-Met inhibitor 1
-
NoteResearch use only, not for human use.
-
Brief Descriptionc-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.
-
Descriptionc-Met inhibitor 1 is a c-Met receptor signaling pathway inhibitor, used for the treatment of cancer including glioblastoma, gastric, and pancreatic cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
Targetc-Met/HGFR
-
Recptorc-Met
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1357072-61-7
-
Formula Weight362.41
-
Molecular FormulaC17H14N8S
-
Purity>98% (HPLC)
-
SolubilityDMSO:18 mg/mL (49.67 mM; Need ultrasonic)
-
SMILESCn1cc(cn1)-c1ccc2nnc(Sc3ccc4nn(C)cc4c3)n2n1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. PCT Int. Appl. (2012), WO 2012015677 A1 20120202.
molnova catalog
related products
-
Glumetinib
Glumetinib (SCC 244)?is a novel potent and highly selective inhibitor of c-Met kinase with IC50 of 0.42 nM.
-
MET inhibitor Compou...
A novel potent, selective orally bioavailable MET tyrosine kinase inhibitor with IC50 of <1 nM and 12 nM for unphosphorylated and phosphorylaed MET, respectively.
-
PLB-1001
PLB-1001 (Bozitinib, PLB1001, CBI-3103, CBT-101) is a potent, highly selective, ATP-competitive, BBB-permeable MET kinase inhibitor, potently inhibits MET activity by 95.1% at 2 uM.
